智通财经APP讯，莱伯泰科(688056.SH)披露2025年度业绩快报，报告期内，公司实现营业收入4.02亿 元，同比减少5.14%;实现归属于母公司所有者的净利润3938万元，同比增长0.59%。 报告期内全线产品综合毛利率保持平稳，与上年同期基本持平;同时，公司在整体成本费用管理上持续 控制，提升效率，报告期内各项期间费用绝对金额均有不同程度的下降。 ...

证券日报网讯 2月27日，莱伯泰科发布2025年度业绩快报公告称，公司2025年实现营业总收入40， 223.06万元，同比减少5.14%；归属于母公司所有者的净利润3，938.00万元，同比增长0.59%。 （文章来源：证券日报） ...

报告期内全线产品综合毛利率保持平稳，与上年同期基本持平；同时，公司在整体成本费用管理上持续 控制，提升效率，报告期内各项期间费用绝对金额均有不同程度的下降。 格隆汇2月27日丨莱伯泰科(688056.SH)公布2025年年度业绩快报，报告期内，公司实现营业收入 40,223.06万元，同比减少5.14%；实现营业利润4,561.04万元，同比增长4.26%；实现利润总额4,541.29 万元，同比增长3.83%；实现归属于母公司所有者的净利润3,938.00万元，同比增长0.59%；实现归属于 母公司所有者的扣除非经常性损益的净利润3,305.95万元，同比增长6.77%。 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2026-002 北京莱伯泰科仪器股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以北京莱伯泰科仪器股份有限公司（以下简称"公司"）2025年年 度报告中披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 2.以上财务数据及指标以合并报表数据填制，尚未经审计，最终数据以公司 2025 年年 度报告中披露的数据为准。 1 二、经营业绩和财务状况情况说明 报告期内，公司实现营业收入 40,223.06 万元，同比减少 5.14%；实现营业 利润 4,561.04 万元，同比增长 4.26%；实现利润总额 4,541.29 万元，同比增长 3.83%；实现归属于母公司所有者的净利润 3,938.00 万元，同比增长 0.59%；实 现归属于母公司所有者的扣除非经常性损益的净利润 3,305.95 万元，同比增长 6.77%。报 ...

莱伯泰科公告称，2025年公司实现营业收入40,223.06万元，同比减少5.14%；实现归属于母公司所有者 的净利润3,938.00万元，同比增长0.59%；实现扣除非经常性损益的净利润3,305.95万元，同比增长 6.77%。报告期末总资产93,301.55万元，较年初减少2.37%；归属于母公司的所有者权益80,925.15万 元，较年初减少1.02%。数据为初步核算，未经审计，具体以年报为准。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1 - The article highlights various job openings in the instrumentation sector, emphasizing the demand for skilled sales engineers and technical roles across multiple companies [3][4][5][6][7][8][9][10][12][13][16][17][18][19][20][22][24][27][29][35][36] - Positions require a range of qualifications, typically a bachelor's degree or higher in relevant fields such as chemistry, biology, or engineering, with many roles preferring candidates with prior sales experience in the instrumentation or related industries [6][9][12][19][22][35] - Salary ranges for these positions vary significantly, with some roles offering monthly salaries between 8,000 to 55,000 RMB, depending on experience and specific job responsibilities [4][7][18][27][35] Group 2 - Companies are looking for candidates with strong interpersonal skills, the ability to work under pressure, and a commitment to continuous learning and professional development [6][9][12][19][22][35] - Many job descriptions emphasize the importance of technical knowledge related to laboratory instruments and the ability to provide solutions tailored to client needs [16][19][22][35] - The article indicates a trend towards remote collaboration and the use of CRM and data analysis tools in sales processes, reflecting the evolving nature of the industry [12][19][22][35]

有投资者在互动平台向莱伯泰科提问："请问公司近年是否存在向欧盟成员国出口或销售的相关业务？ 如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售主要 通过哪种方式实现：是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进行销 售，或通过第三方贸易商、代理商转销至欧盟市场？" 针对上述提问，莱伯泰科回应称："这位投资者您好，非常感谢您的支持与关注！近年来公司正积极扩 展欧洲市场业务，公司对欧洲市场的销售主要通过经销商进行销售。具体经营情况及财务数据，可查阅 公司在上海证券交易所网站披露的定期报告，谢谢。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 作者：公告君 ...

Core Insights - The development of microwave digestion instruments is closely linked to national strategic needs in environmental monitoring, food safety, drug research, and life sciences, with the market size expected to reach approximately 2.467 billion yuan in 2024, reflecting a year-on-year growth of 10.28% [1][4][7]. Industry Overview - Microwave digestion instruments utilize microwave heating technology for rapid sample digestion, achieving high temperatures and pressures to accelerate chemical reactions, resulting in faster processing times and higher sample recovery rates compared to traditional methods [2][3]. Industry Development History - The microwave digestion instrument industry in China has evolved over three decades, starting from the initial phase (1988-2000) with foundational research and patent developments, followed by a growth phase (2001-2016) focusing on technology promotion and standardization, and reaching a mature phase (2017-present) where domestic brands have made significant advancements [4][5]. Industry Value Chain - The industry value chain includes upstream components such as TFM, PTFE, and microwave reactors, midstream manufacturing of microwave digestion instruments, and downstream applications in environmental monitoring, food testing, pharmaceuticals, and biomedical fields [6]. Market Size - The market for microwave digestion instruments is projected to grow significantly, driven by increasing demands for efficiency and accuracy in sample preparation across various sectors, with a market size of approximately 2.467 billion yuan anticipated for 2024 [1][4][7]. Key Companies' Performance - The competitive landscape has shifted from being dominated by imported brands to a clear tiered system led by domestic brands such as Haineng Technology and Laibotai Technology, which hold significant market shares due to technological barriers and large-scale production [8][9]. Industry Development Trends 1. The industry is expected to transition from "single devices" to "intelligent systems" through the integration of AI algorithms and IoT technologies, enhancing efficiency and reducing human error [10]. 2. Environmental performance will become a key competitive factor, with a focus on reducing reagent consumption and waste emissions, as well as utilizing more sustainable materials [11][12]. 3. The market will see a restructuring of competition, with domestic brands leading and new enterprises breaking into niche markets, while also expanding internationally [13].

Group 1 - The company Leibotech responded to investor inquiries on January 12, indicating that shareholders should pay attention to relevant announcements regarding the equity transfer matter [2]